01. Methodology Overview
The Wolverine Stack methodology relies on the biological synergy between BPC-157's angiogenic properties (creating new blood vessels) and TB-500's action on actin upregulation (cellular migration). Together, they target the three phases of tissue repair:
- Inflammatory Phase: Modulation of acute cytokine response.
- Proliferative Phase: Accelerated fibroblast migration and collagen synthesis.
- Remodeling Phase: Structural reinforcement of newly formed tissue.
02. Component Architecture
The Systemic Shield
Derived from human gastric juice, this peptide is highly stable and targets the G-H axis to facilitate blood vessel growth (angiogenesis).
- Collagen expression focus
- Gastric stability (Oral viable)
The Cellular Architect
A synthetic fragment of a naturally occurring protein found in high concentrations in platelets and wound fluid.
- Cell migration & Actin focus
- Systemic inflammation management
03. Protocol Comparison Grid
| Phase | Timeline | Description | Oversight |
|---|---|---|---|
| Phase 0 (Intake) | Days 1-14 | Comprehensive lab work and physician consultation. | Mandatory MD review. |
| Phase 1 (Loading Phase) | Weeks 1-4 | Initiation of localized BPC-157 alongside systemic TB-500 to address acute inflammation. | Weekly symptom monitoring. |
| Phase 2 (Maintenance) | Weeks 5-12 | Tapered protocol focused on deep tissue remodeling. | Monthly metabolic panel check. |
Safety & Regulatory Matrix
Regulatory Red Flags
- 01. WADA S2 Category: TB-500 is banned at all times for tested athletes.
- 02. Research-Only Status: Not approved by the FDA for human administration.
Biological Risks
- ! Angiogenesis Risk: High doses theorized to potentially feed existing occult malignancies.
- ! Purity Issues: Heavy metal contamination in non-verified "research chemical" batches.
Find a Verified Protocol Clinic
Connect with certified specialists under Dr. Bussel's guidance.
06. Practitioner FAQ
Primary Literature & Sources
View Full Database[1] BPC-157 as a therapeutic agent in muscle/tendon healing
J. Orthop. Res (2021)[2] Thymosin β4 facilitates repair of rat Achilles tendon
Wound Repair Regen (2018)